The fixed-dose combination medication xanomeline/trospium chloride (Cobenfy) was approved for medical use in the United States in September 2024. It is the first cholinergic agonist approved by the US Food and Drug Administration (FDA) to treat schizophrenia.
The fixed-dose combination medication xanomeline/trospium chloride (Cobenfy) was approved for medical use in the United States in September 2024. It is the first cholinergic agonist approved by the US Food and Drug Administration (FDA) to treat schizophrenia.